Combined Anterior-Posterior Versus Posterior-only Spinal Fusion in Treating Dystrophic Neurofibromatosis Scoliosis With Modern Instrumentation A Systematic Review and Meta-analysis

Study Design: This is a systematic review and meta-analysis study. Objectives: To compare the efficacy, long-term stability, and safety of combined anterior-posterior spinal fusion (APSF) with posterior-only spinal fusion (PSF) in treating dystrophic neurofibromatosis scoliosis with the use of modern instrumentation. Summary of Background Data: When the Harrington or Luque technique was used, APSF had relatively reliable results and had been recommended by many authors. But with the development of instrumentation and techniques, many surgeons performed PSF with satisfactory results. No systematic review and meta-analysis have been conducted to compare the outcomes of the 2 approaches. Materials and Methods: Relevant studies on anterior-posterior or posterior fusion of dystrophic neurofibromatosis scoliosis were retrieved from the PubMed, Embase, Cochrane, Springer Link, and Google Scholar databases. Then studies were manually selected for inclusion based on predefined criteria. Data extraction and quality assessment were conducted, and a systematic review and meta-analysis were performed. Results: Sixteen eligible studies were included. The angles of scoliosis curves and kyphosis curves were significantly and similarly corrected after surgery in both APSF and PSF group, respectively. At the last follow-up, the loss of correction was significant in the coronal plane but not in the sagittal plane with a similar progression of scoliosis in 2 groups. The overall complication rate was slightly higher in the APSF group, but the difference was not statistically significant. Meanwhile, there was no visible difference in the incidence of pseudarthrosis and instrumentation failures between the 2 groups. Conclusions: APSF and PSF by means of the third-generation spinal instrumentation system have similar efficacy, long-term stability, and safety for treating dystrophic scoliosis secondary to type-1 neurofibromatosis.